Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vanda Pharmaceuticals Inc. (VNDA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Vanda describes its commercial portfolio, clinical pipeline, financial condition, and interactions with the U.S. Food and Drug Administration.
Recent Form 8-K filings referenced by Vanda include earnings announcements and disclosures about a collaborative framework with the FDA regarding HETLIOZ (tasimelteon) and tradipitant. Through these current reports, investors can review management’s discussion of net product sales for Fanapt, HETLIOZ, and PONVORY, as well as updates on NDAs and BLAs for programs such as Bysanti, tradipitant in motion sickness, and imsidolimab in generalized pustular psoriasis.
On Stock Titan, VNDA filings are updated in near real time from EDGAR and paired with AI-powered summaries that explain the key points of lengthy documents. For annual reports on Form 10-K and quarterly reports on Form 10-Q, AI highlights sections related to Vanda’s commercial products, research and development spending, and risk factors tied to regulatory decisions and clinical trial outcomes. For current reports on Form 8-K, AI summaries focus on the specific material events being disclosed, such as financial results or significant regulatory agreements.
Users can also review other SEC forms associated with VNDA, including exhibits attached to 8-K filings that contain press releases or detailed descriptions of regulatory milestones. For investors analyzing Vanda’s work in sleep-wake disorders, psychiatric conditions, motion sickness, and rare inflammatory skin disease, these filings provide a structured view of the company’s obligations, forward-looking statements, and disclosed risks, while the AI tools on Stock Titan help make the technical language more accessible.
Vanda Pharmaceuticals Inc. has filed a shelf registration to offer up to
The securities may be sold directly, through agents, or via underwriters, and net proceeds are intended for general corporate purposes. Vanda’s common stock trades on the Nasdaq Global Market under the symbol VNDA, with a last reported sale price of
Vanda Pharmaceuticals Inc. files its annual report outlining 2025 product sales and a broad late-stage pipeline. The company generated 2025 net sales of $117.3 million from Fanapt, $71.4 million from HETLIOZ, $27.4 million from PONVORY, and no reported U.S. sales yet for its newly approved motion sickness drug.
Vanda markets four commercial products and is advancing multiple late-stage programs, including an NDA for milsaperidone in bipolar I disorder and schizophrenia, an NDA for tradipitant in gastroparesis, and a BLA for imsidolimab in generalized pustular psoriasis. The company faces significant risks from generic HETLIOZ competition, complex FDA interactions on several indications, reliance on a few major customers, and extensive patent and regulatory litigation while pursuing global expansion and new indications.
Vanda Pharmaceuticals reported full year 2025 total revenues of
GAAP net loss widened to
Operationally, the FDA approved NEREUS (tradipitant) for prevention of motion-induced vomiting, while Bysanti (milsaperidone) has a PDUFA target action date of
BlackRock Portfolio Management LLC has filed an amended Schedule 13G reporting a beneficial ownership stake in Vanda Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 3,251,563 shares, representing 5.5% of the class as of the event date 12/31/2025. BlackRock Portfolio Management LLC has sole voting power over 2,796,972 shares and sole dispositive power over 3,251,563 shares, with no shared voting or dispositive power.
The filing explains that the holdings are aggregated from certain BlackRock business units and are held in the ordinary course of business. It also certifies that the securities were not acquired for the purpose of changing or influencing control of Vanda Pharmaceuticals Inc., indicating a passive investment position under the Schedule 13G framework.
Vanda Pharmaceuticals Inc. received an amended Schedule 13G/A from Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reporting a passive ownership position. The group reports beneficial ownership of 1,679,013 shares of Vanda common stock, representing 2.8% of the outstanding class as of the 12/31/2025 event date. All voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power. The filers state that the securities were not acquired and are not held for the purpose of changing or influencing control of Vanda, but instead are held on a passive basis.
Vanda Pharmaceuticals reports that the U.S. Food and Drug Administration has completed an expedited re-review of its supplemental New Drug Application for HETLIOZ as a treatment for jet lag disorder and concluded the application cannot be approved in its current form. This re-review was conducted under a previously announced collaborative framework between Vanda and the FDA, with a target date of January 7, 2026. The decision represents a setback for Vanda’s efforts to add jet lag disorder as a new indication for HETLIOZ. Vanda issued a press release on January 8, 2026, and has attached the full text as an exhibit.
Vanda Pharmaceuticals (VNDA) reported a larger quarterly loss despite higher sales. Net product sales were $56.3 million in Q3 2025, up from $47.7 million a year ago. Sales by product: Fanapt $31.2 million, HETLIOZ $18.0 million, and PONVORY $7.0 million.
Operating expenses rose sharply, with selling, general and administrative at $60.3 million (from $37.6 million) and research and development at $22.6 million (from $16.8 million). Loss from operations was $31.3 million; net loss was $22.6 million, or $0.38 per share. For the nine months, revenue reached $158.9 million with a net loss of $79.3 million. Operating cash flow was an outflow of $80.0 million year-to-date.
Liquidity remained significant: cash and cash equivalents were $70.0 million and marketable securities were $223.7 million as of September 30, 2025. Total assets were $601.1 million and stockholders’ equity was $466.0 million. The company noted HETLIOZ sales may be variable and could decline in future periods related to generic competition. Shares outstanding were 59,096,630 as of October 23, 2025.
Vanda Pharmaceuticals (VNDA) furnished an 8‑K stating it issued a press release and is holding a conference call regarding results of operations and financial condition for the quarter ended September 30, 2025.
The press release is included as Exhibit 99.1 and, along with Item 2.02, is furnished and not deemed “filed” under the Exchange Act. The company also included standard forward‑looking statements cautions, directing readers to risk factors in its periodic SEC reports.
Vanda Pharmaceuticals Inc. reported that it has reached a collaborative framework with the U.S. Food and Drug Administration to resolve certain disputes involving its drugs HETLIOZ® (tasimelteon) and tradipitant. This means the company and the FDA have agreed on a structured approach to address outstanding regulatory disagreements related to these products.
The company announced this development in a press release dated October 1, 2025, which is referenced as an exhibit. While specific terms or outcomes are not described here, the framework focuses on moving toward resolution of the disputes regarding these two drugs.
Mihael H. Polymeropoulos, identified as President and CEO (also listed as a director and chairman), reported a purchase of 10,000 shares of Vanda Pharmaceuticals common stock on 08/07/2025 at $4.15 per share. After this purchase he beneficially owns 2,335,731 shares. The Form 4 discloses a direct insider buy by the company’s chief executive, increasing his reported stake.
FAQ
What is the current stock price of Vanda Pharma (VNDA)?
What is the market cap of Vanda Pharma (VNDA)?
